The New England journal of medicine, 2019-10, Vol.381 (14), p.1309-1320
- Steg, P. Gabriel
- Bhatt, Deepak L
- Simon, Tabassome
- Fox, Kim
- Mehta, Shamir R
- Harrington, Robert A
- Held, Claes
- Andersson, Marielle
- Himmelmann, Anders
- Ridderstråle, Wilhelm
- Leonsson-Zachrisson, Maria
- Liu, Yuyin
- Opolski, Grzegorz
- Zateyshchikov, Dmitry
- Ge, Junbo
- Nicolau, José C
- Corbalán, Ramón
- Cornel, Jan H
- Widimský, Petr
- Leiter, Lawrence A
2019
Details
- Autor(en) / Beteiligte
- Steg, P. Gabriel
- Bhatt, Deepak L
- Simon, Tabassome
- Fox, Kim
- Mehta, Shamir R
- Harrington, Robert A
- Held, Claes
- Andersson, Marielle
- Himmelmann, Anders
- Ridderstråle, Wilhelm
- Leonsson-Zachrisson, Maria
- Liu, Yuyin
- Opolski, Grzegorz
- Zateyshchikov, Dmitry
- Ge, Junbo
- Nicolau, José C
- Corbalán, Ramón
- Cornel, Jan H
- Widimský, Petr
- Leiter, Lawrence A
- Titel
- Ticagrelor in Patients with Stable Coronary Disease and Diabetes
- Ist Teil von
- The New England journal of medicine, 2019-10, Vol.381 (14), p.1309-1320
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with stable coronary artery disease and diabetes were randomly assigned to receive either ticagrelor plus aspirin or placebo plus aspirin. At 40 months, the incidence of the composite efficacy outcome of cardiovascular death, myocardial infarction, or stroke was lower with ticagrelor than with placebo; the frequency of major bleeding was higher with ticagrelor.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa1908077Titel-ID: cdi_swepub_primary_oai_DiVA_org_uu_395718
- Format
- –
- Schlagworte
- Aged, Aspirin, Aspirin - adverse effects, Aspirin - therapeutic use, Bleeding, Blood platelets, Cardiovascular disease, Cardiovascular diseases, Cerebral infarction, Control, Coronary artery, Coronary Artery Disease - complications, Coronary Artery Disease - drug therapy, Coronary Artery Disease - mortality, Coronary heart disease, Coronary vessels, Design, Diabetes, Diabetes mellitus, Diabetes mellitus (non-insulin dependent), Diabetes Mellitus, Type 2 - complications, Diabetes Mellitus, Type 2 - drug therapy, Diabetes Mellitus, Type 2 - mortality, Double-Blind Method, Drug therapy, Drug Therapy, Combination - adverse effects, Female, Follow-Up Studies, Heart attacks, Heart diseases, Hemorrhage, Hemorrhage - chemically induced, Hemorrhage - epidemiology, Hemorrhage - mortality, Human health and pathology, Humans, Incidence, Ischemia, Kaplan-Meier Estimate, Life Sciences, Male, Middle Aged, Myocardial infarction, Myocardial Infarction - epidemiology, Myocardial Infarction - prevention & control, Platelet Aggregation Inhibitors - adverse effects, Platelet Aggregation Inhibitors - therapeutic use, Population, Research centers, Safety and security measures, Stroke, Stroke - epidemiology, Stroke - prevention & control, Thrombolysis, Thrombosis, Ticagrelor, Ticagrelor - adverse effects, Ticagrelor - therapeutic use, Treatment Outcome